Carin A. Uyl-De Groot

Carin A. Uyl-De Groot

Auto-generated profile, based on publicly available information

Carin A. Uyl-De Groot

Erasmus School of Health Policy & Management/institute for Medical Technology Assessment, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR Rotterdam, the Netherlands.

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2003 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
TGthe PLUS study group
the PLUS study group
PVPaul Verboom
Paul Verboom
HTHarm van Tinteren
Harm van Tinteren
OHOtto S. Hoekstra
Otto S. Hoekstra
ESEgbert F. Smit
Egbert F. Smit
CGCarin A. Uyl-De Groot
Carin A. Uyl-De Groot

1 February 2010 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
CGCarin A. Uyl-De Groot
Carin A. Uyl-De Groot
ASAsaf Senft
Asaf Senft
RBRemco de Bree
Remco de Bree
CLC. René Leemans
C. René Leemans
OHOtto S. Hoekstra
Otto S. Hoekstra
The aim of the study was to define the cost-effectiveness of whole-body 18F-FDG PET, as compared with chest CT, in screening for distant metastases in patients with head and neck squamous cell carcinoma (HNSCC). Methods: In a multicenter prospective study, 145 consecutive patients with high risk factors for distant metastases and scheduled for extensive treatment underwent chest CT and whole-body 18F-FDG PET for screening of distant metastases. The cost data of 80 patients in whom distant metastases developed or who had a follow-up of at least 12 mo were analyzed. Cost-effectiveness analysis, including sensitivity analysis, was performed to compare the results of 18F-FDG PET, CT, and a combination of CT and 18F-FDG PET (CT + 18F-FDG PET). Results: Pretreatment screening identified distant metastases in 21% of patients. 18F-FDG PET had a higher sensitivity (53% vs. 37%) and positive predictive value (80% vs. 75%) than did CT. CT + 18F-FDG PET had the highest sensitivity (63%). The average costs in the CT, 18F-FDG PET, and CT + 18F-FDG PET groups amounted to €38,558 (≈$57,705), €38,355 (≈$57,402), and €37,954 (≈$56,801), respectively, in the first year after screening. CT + 18F-FDG PET resulted in savings between €203 (≈$303) and €604 (≈$903). Sensitivity analysis showed that the dominance of CT + 18F-FDG PET was robust. Conclusion: In HNSCC patients with risk factors, pretreatment screening for distant metastases by chest CT is improved by 18F-FDG PET. The combination of 18F-FDG PET with CT is the most effective, without leading to additional costs.

1 February 2016 in Oral Oncology
Verified
Journal Article
Closed access
NLNaomi van der Linden
Naomi van der Linden
GFGéke B. Flach
Géke B. Flach
Remco De BreeRemco De Bree
Remco De Bree
CGCarin A. Uyl-De Groot
Carin A. Uyl-De Groot

3 February 2015 in PharmacoEconomics
Verified
Journal Article
Open access
PDF file
HBHedwig M. Blommestein
Hedwig M. Blommestein
MFMargreet G. Franken
Margreet G. Franken
CGCarin A. Uyl-De Groot
Carin A. Uyl-De Groot
Decision makers increasingly request evidence on the real-world cost effectiveness of a new treatment. There is, however, a lack of practical guidance on how to conduct an economic evaluation based on registry data and how this evidence can be used in actual decision making. This paper explains the required steps on how to perform a sound economic evaluation using examples from an economic evaluation conducted with real-world data from the Dutch Population based HAematological Registry for Observational Studies. There are three main issues related to using registry data: confounding by indication, missing data, and insufficient numbers of (comparable) patients. If encountered, it is crucial to accurately deal with these issues to maximize the internal validity and generalizability of the outcomes and their value to decision makers. Multivariate regression modeling, propensity score matching, and data synthesis are well-established methods to deal with confounding. Multiple imputation methods should be used in cases where data are missing at random. Furthermore, it is important to base the incremental cost-effectiveness ratio of a new treatment compared with its alternative on comparable groups of (matched) patients, even if matching results in a small analytical population. Unmatched real-world data provide insights into the costs and effects of a treatment in a real-world setting. Decision makers should realize that real-world evidence provides extremely valuable and relevant policy information, but needs to be assessed differently compared with evidence derived from a randomized clinical trial.

1 February 2001 in Journal of Hematotherapy & Stem Cell Research
Verified
Journal Article
Closed access
CGC.A. Uyl-De Groot
C.A. Uyl-De Groot
JHJ. Gelderblom-Den Hartog
J. Gelderblom-Den Hartog
PHP.C. Huijgens
P.C. Huijgens
RWR. Willemze
R. Willemze
BIB.M. van Ineveld
B.M. van Ineveld
The aim of the study was to calculate the costs in various places of acute myeloid leukemia (AML). Patients less than 65 years old, who were treated for newly diagnosed AML were included. The cost analysis distinguished between diagnosis, treatment, follow-up (maximum of 2 years), and treatment of relapse. The treatment period was divided into remission induction and consolidation treatment, harvest of bone marrow (BM) or peripheral blood stem cells, and transplantation. The costs of diagnosis amounted to $3,167 (1995 US$). Remission-induction treatments cost on average $46,387 and harvest of bone marrow or peripheral blood stem cells costs $6,491. The costs of the transplantation varied between $25,531 and $44,087. Costs of follow-up amounted to $4,167. Relapse treatment, mainly consisting of reinduction therapy, costs on average $24,338. The total average weighted costs of AML patients amounted to $104,386. Treating AML patients is very expensive, and major reductions in costs are not expected in the next future. Considering efficacy and effectiveness, it seemed that choices based on costs could be made between several consolidation techniques and between a specific consolidation technique and/or palliative treatment.

21 January 2015 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Open access
PDF file
NLNaomi van der Linden
Naomi van der Linden
JBJan Buter
Jan Buter
CPChris P. Pescott
Chris P. Pescott
RLRoy Lalisang
Roy Lalisang
JBJan Paul de Boer
Jan Paul de Boer
CGCarin A. Uyl-De Groot
Carin A. Uyl-De Groot
For patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), chemotherapy can prolong life and alleviate symptoms. However, expected gains may be small, not necessarily outweighing considerable toxicity and high costs. Treatment choice is to a large extent dependent on preferences of doctors and patients and data on these choices are scarce. The purpose of this study is to obtain real-world information on palliative systemic treatment and costs of R/M SCCHN in the Netherlands. In six Dutch head and neck treatment centers, data were collected on patient and tumor characteristics, treatment patterns, disease progression, survival, adverse events, and resource use for R/M SCCHN, between 2006 and 2013. 125 (14 %) out of 893 R/M SCCHN patients received palliative, non-trial first-line systemic treatment, mainly platinum + 5FU + cetuximab (32 %), other platinum-based combination therapy (13 %), methotrexate monotherapy (27 %) and capecitabine monotherapy (14 %). Median progression-free survival and overall survival were 3.4 and 6.0 months, respectively. 34 (27 %) patients experienced severe adverse events. Mean total hospital costs ranged from €10,075 (±€9,891) (methotrexate monotherapy) to €39,459 (±€21,149) (platinum + 5FU + cetuximab). Primary cost drivers were hospital stays and anticancer drug treatments. Major health care utilization and costs are involved in systemically treating R/M SCCHN patients with a limited survival.